Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Cancer
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung...
IN8bio Announces Pricing of $12.4 Million Private Placement
Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update...
Canadian Dermatology Association (CDA) Announces 2025 Shade Structure Grant Recipients
OTTAWA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association is proud to announce the recipients of the 2025...
Spago Nanomedical in New Phase with Full Focus on the Tumorad Program
LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB...
AlzeCure’s Abstract on ACD856’s Anti-inflammatory Effects to be Presented at a Leading Alzheimer’s Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Electronic Caregiver and Samsung Electronics America Join Forces to Reveal Transformational Chronic and Aging Care Solutions at HLTH 2024
Addressing the Challenge of Chronic Conditions with Addison Care and Samsung Electronics America LAS VEGAS, Sept. 30, 2024 /PRNewswire/ -- Today,...
Dovetail Genomics Launches Certified Service Provider Program to Expand Access to Hi-C Through Partnerships with Premier Service Labs
SCOTTS VALLEY, Calif., Sept. 30, 2024 /PRNewswire/ -- Dovetail Genomics, a pioneer in Hi-C genomic services, is proud to announce...
Cortechs.ai Announces Strategic Partnership with Ascend Imaging to Expand Access to Cutting-Edge Radiology Solutions
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Cortechs.ai, a leader in advanced imaging software medical analysis, is proud to announce...
Genomics plc Announces David Thornton as President
OXFORD, England, Sept. 30, 2024 /PRNewswire/ -- Genomics plc, a healthcare company using large-scale genetic information to develop innovative precision...
Study Indicates Significant Radiation Reduction for Breast Cancer Patients
Lumpectomy Patients Received VeraForm® Marker and APBI Therapy for Breast Cancer TreatmentSAN FRANCISCO, CA / ACCESSWIRE / September 30, 2024...
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial – Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has...
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM to Exotics
Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first...
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of...
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,...
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer’s Disease
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company...